Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
CA 2443025 A1 · Owner: Mehlhop, Paul · Inventors: Mehlhop, Paul; Sigounas, George
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of reducing organ toxicity in a subject being administered a cytotoxic agent comprising concurrently administering with the cytotoxic agent erythropoietin (EPO), the EPO being administered in an amount effective to reduce pulmonary toxicity caused by the cytotoxic agent.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 8, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 8, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 8, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.